{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:00:04Z","timestamp":1791172804410,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.semnuclmed.2025.11.025","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:25:38Z","timestamp":1766060738000},"page":"18-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapy strategies to defeat prostate cancer heterogeneity"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-2484","authenticated-orcid":false,"given":"Hossein","family":"Jadvar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5835","authenticated-orcid":false,"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0002","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186599","article-title":"Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer","volume":"135","author":"Roudier","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumor heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0004","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/cancers13112795","article-title":"Cell plasticity and prostate cancer: the role of epithelial-mesenchymal transition in tumor progression, invasion, metastasis, and cancer therapy resistance","volume":"13","author":"Papanikolaou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0006","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-021-01319-8","article-title":"Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework","volume":"125","author":"Saini","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0008","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/ERC-16-0049","article-title":"Clonal origin and spraed of metastatic prostate cancer","volume":"23","author":"Van Etten","year":"2016","journal-title":"Endoc Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0009","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0010","article-title":"Interactions between key genes and pathways in prostate cancer progression and therapy resistance","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/path.4826","article-title":"The molecular underpinnings of prostate cancer: impacts on management and pathology practice","volume":"241","author":"Rodrigues","year":"2017","journal-title":"J Pathol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-031-11836-4_15","article-title":"Prostate cancer epigenetic plasticity and enhancer heterogeneity: molecular causes, consequences, and clinical implications","volume":"1390","author":"Kneppers","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jcb.20898","article-title":"Androgen axis in prostate cancer","volume":"99","author":"Culig","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/cancers13020327","article-title":"Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced?","volume":"13","author":"Maitland","year":"2021","journal-title":"Cancer (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0016","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0017","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0018","doi-asserted-by":"crossref","first-page":"459","DOI":"10.20517\/cdr.2022.07","article-title":"Role of prostate stem-like cells in the development of antiandrogen resistance","volume":"5","author":"Kushwaha","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0019","article-title":"Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis","volume":"2017","author":"Harris","year":"2017","journal-title":"Stem Cell Int"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/21681805.2017.1283360","article-title":"Prostate cancer stem cell: from theory to practice","volume":"51","author":"Adamowicz","year":"2017","journal-title":"Scan J Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0021","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","article-title":"Prostate cancer stem cells: a new target for therapy","volume":"26","author":"Maitland","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-030-22254-3_15","article-title":"Tumor dormancy and slow-cycling cancer cells","volume":"1164","author":"Davis","year":"2019","journal-title":"Adv Exp med Biol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.652747","article-title":"Tumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development","volume":"12","author":"Bahmad","year":"2021","journal-title":"Front Genet"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/biom13010067","article-title":"Cancer-associated fibroblast heterogeneity, activation and function. Implications for prostate cancer","volume":"13","author":"Owen","year":"2022","journal-title":"Biomolecules"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0026","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3390\/cancers15174357","article-title":"Lineage plasticity and stemness phenotypes in prostate cancer: harnessing the power of integrated \u201comics\u201d approaches to explore measurable metrics","volume":"15","author":"Logotheti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0027","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.62347\/YFRP8901","article-title":"Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response","volume":"12","author":"Archer","year":"2024","journal-title":"Am J Clin Exp Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/pcmedi\/pbab003","article-title":"Neuroendocrine cells of the prostate: histology, biological functions, and molecular mechanisms","volume":"4","author":"Butler","year":"2021","journal-title":"Precis Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0030","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.12998\/wjcc.v12.i13.2143","article-title":"Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: identification, prognosis, and survival, genetic and epigenetic factors","volume":"12","author":"Wishahi","year":"2024","journal-title":"World J Clin Cases"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0031","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/bs.acr.2024.04.006","article-title":"Understanding the molecular regulators of neuroendocrine prostate cancer","volume":"161","author":"Bhattacharya","year":"2024","journal-title":"Adv Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0032","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0033","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0034","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAFore): a phase 3, randomized, clinical trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0036","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/pros.23729","article-title":"Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy meeting","volume":"79","author":"Miyahira","year":"2019","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0037","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2967\/jnumed.120.256263","article-title":"Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer","volume":"62","author":"Stuparu","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0038","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0039","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-031-45654-1_10","article-title":"Epigenetic (de)regulation in prostate cancer","volume":"190","author":"Xu","year":"2023","journal-title":"Cancer Treat Res"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0041","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-017-0480-2","article-title":"PARP inhibitors in prostate cancer","volume":"18","author":"Geethakumari","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"suppl","key":"10.1053\/j.semnuclmed.2025.11.025_bib0042","first-page":"500","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0043","doi-asserted-by":"crossref","unstructured":"Jadvar H., Rahbar K., Ahmadzadehfar H., et al. Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer. Q J Nucl Med Mol Imaging 69:174-179.","DOI":"10.23736\/S1824-4785.25.03641-6"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0044","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","article-title":"The Cancer Surfaceome Atlas integrates genomic, functional, and drug response data to identify actionable targets","volume":"2","author":"Hu","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55291-x","article-title":"The Theranostic Genome","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01037-9","article-title":"Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer","author":"Ashraf","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2025.11.025_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104653","article-title":"Revolutionizing prostate cancer therapy: artificial intelligence-based nanocarriers for precision diagnosis and treatment","volume":"208","author":"Shirzad","year":"2025","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:08:58Z","timestamp":1771218538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001299825001783"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.025","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy strategies to defeat prostate cancer heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}